Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Losmapimod
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Losmapimod for COVID-19
1
study with
48
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Losmapimod studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Losmapimod
reduces riskIncreased risk → |
Mar 31 2021 |
et al., NCT04511819 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY) |
| 18% higher progression (p=0.54) and 14% worse recovery (p=0.64). RCT 52 hospitalized COVID-19 patients showing no significant differences with losmapimod treatment. | ||
